Characterisation of non-visual function in healthy participants Not Applicable
Conditions
Interventions
The participants will attend four in-laboratory sessions over a total study period of 3 weeks, including an initial circadian stabilisation period of 1 week. Participants will spend a total of 6 hours
Sponsors
Max Planck Institute for Biological Cybernetics
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Current participant inclusion criteria as of 12/07/2023: 1. Age, =18, =40 years of age, Self-report 2. Physical health, Good physical health, Self-report 3. Mental health, Good mental health, Self-report 4. Ocular health, Good ocular health (self-report) 5. Binocular vision, Titmus Fly Test 6. Visual acuity, Normal or corrected-to-normal visual acuity, Landolt C (20/30 or better) 7. Colour vision, Normal colour vision, Cambridge Colour Test, anomaloscope Previous participant inclusion criteria: 1. Age, =18, =40 years of age, Self-report 2. Physical health, Good physical health, Self-report 3. Mental health, Good mental health, Self-report 4. Ocular health, Good ocular health, Ophthalmological examination by ophthalmologist 5. Binocular vision, , Titmus Fly Test 6. Visual acuity, Normal or corrected-to-normal visual acuity, Landolt C 7. Colour vision, Normal colour vision, Cambridge Colour Test, anomaloscope
Exclusion criteria
Exclusion criteria: Current participant inclusion criteria as of 12/07/2023: 1. BMI, 30, Calculation from self-reported and/or measured height and weight 2. Medication use, Any use of medications, Self-report 3. Smoking, Habitual smoking, Self-report 4. Epilepsy, Diagnosis of epilepsy in self or close relatives with epilepsy (parents, siblings, children), Self-report 5. Substance abuse, Excessive alcohol use, AUDIT > 7 6. Sleep, Poor sleep quality, PSQI >5 7. Chronotype, Extreme chronotype, MCTQ 8. Shift work, No shift work in the past 3 months, Self-report 9. Time zone travel, No inter-time zone travel with more than 1-hour difference in the past 3 months, Self-report 10. Excessive daytime sleepiness, ESS > 12 11. Exogenous hormone intake, including hormonal contraceptives, Self-report 12. Pregnant or breastfeeding, Self-report 13. Hormonal disorders, Self-report 14. Frequent severe physical symptoms related to the menstrual cycle (headache, fever, nausea, vomiting, severe pain), Self-report Previous participant inclusion criteria: 1. BMI, 30, Calculation from measured height and weight 2. Medication use, Any use of medications, Self-report 3. Smoking, Habitual smoking, Self-report 4. Epilepsy, Diagnosis of epilepsy, Self-report 5. Substance abuse, Excessive alcohol use, AUDIT 6. Sleep, Poor sleep quality, PSQI >5 7. Chronotype, Extreme chronotype, MEQ 9. Shift work, No shift work in the past 3 months, Self-report 10. Time zone travel, No inter-time zone travel in the past 3 months, Self-report
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Salivary melatonin concentrations measured using a melatonin hormone testing kit at half-hour intervals during a 5-hour evening protocol | — |
Secondary
| Measure | Time frame |
|---|---|
| The following secondary outcome measures are measured at half-hour intervals during a 5-hour evening protocol: 1. Vigilance measured using the Psychomotor Vigilance Test (PVT) 2. Sleepiness measured using the Karolinska Sleepiness Scale (KSS) 3. Visual comfort measured using a self-report questionnaire | — |
Countries
Germany
Contacts
Public ContactMaydel Fernandez Alonso
Outcome results
None listed